Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Nina Sonne"'
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard. Interestingly, these molecules have several overlapping
Externí odkaz:
https://doaj.org/article/c71fe40f440c43deb8dae3b003dd4193
Publikováno v:
Biomedicines, Vol 10, Iss 10, p 2365 (2022)
Background: Dual Amylin and Calcitonin Receptor Agonists (DACRAs) are treatment candidates for obesity and type 2 diabetes. Recently, a once-weekly DACRA (KBP-A) showed promise, potentially due to its different exposure profile compared to daily DACR
Externí odkaz:
https://doaj.org/article/6425aa391afa4888abc1d5be6ca5c1f1
Publikováno v:
Molecular Metabolism, Vol 46, Iss , Pp 101109- (2021)
Background: Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and
Externí odkaz:
https://doaj.org/article/b3d870e346124d019b76c2e83c2d843c
Publikováno v:
Langenbeck's Archives of Surgery. 406:2367-2373
The optimal timing for laparoscopic cholecystectomy for acute cholecystitis (AC) has not been resolved. In the revised Tokyo Guidelines from 2018 (TG18), early laparoscopic cholecystectomy (ELC) is recommended regardless of the duration of symptoms.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1638fa7a6db1fb4ab944425e8fb4e8ea
https://doi.org/10.1007/s00423-021-02229-2
https://doi.org/10.1007/s00423-021-02229-2
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Endocrine Disorders
BMC Endocrine Disorders
Background Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard. Interestingly, these molecules have several overlapping pharmacol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c2adf23bbf84aa4d57fac2c77590782
https://doaj.org/article/c71fe40f440c43deb8dae3b003dd4193
https://doaj.org/article/c71fe40f440c43deb8dae3b003dd4193
Publikováno v:
Diabetes. 71
Dual amylin and calcitonin receptor agonists (DACRAs) are known to induce a significant weight loss and improve glucose tolerance and glucose control in rats. However, it is unknown if DACRAs has an insulin sensitizing effect beyond that induced by w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0066b42301f380d04a66445be155857d
https://doi.org/10.2337/db22-824-p
https://doi.org/10.2337/db22-824-p
Autor:
ANNA T. LARSEN, NINA SONNE, KHALED ELHADY MOHAMED, EMMA-MARIE BREDTOFT, FREDERIK ANDERSEN, MORTEN A. KARSDAL, KIM HENRIKSEN
Publikováno v:
Diabetes. 71
Long-acting dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for treatment of type 2 diabetes (T2D) and obesity due to their beneficial effects on both body weight, glucose control and insulin action. Cagrilintide, which is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25517a532ff0850702c45c3b16a56cfb
https://doi.org/10.2337/db22-823-p
https://doi.org/10.2337/db22-823-p
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 374:74-83
Amylin treatment improves body weight and glucose control, although it is limited by a short action and need for high doses. Dual amylin and calcitonin receptor agonists (DACRAs) are dual amylin and calcitonin receptor agonists with beneficial effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649b6476f50f13fbc96a8d506a871e8f
https://doi.org/10.1124/jpet.119.263392
https://doi.org/10.1124/jpet.119.263392
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 373:92-102
Pharmacological treatment with Dual Amylin and Calcitonin Receptor Agonists (DACRAs) cause a significant weight loss and improvement of glucose homeostasis. In this study, the maximally efficacious dose of the novel DACRA, KBP-066, was investigated.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43cf0b496ca01331144b2a815204116
https://doi.org/10.1124/jpet.119.263723
https://doi.org/10.1124/jpet.119.263723
Publikováno v:
Molecular Metabolism, Vol 53, Iss, Pp 101282-(2021)
Molecular Metabolism
Molecular Metabolism
Objective Dual amylin and calcitonin receptor agonists (DACRAs) are novel therapeutic agents that not only improve insulin sensitivity but also work as an adjunct to established T2DM therapies. DACRAs are currently administered once daily, though it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42a40bb8ac61c7b01924bdd39a5ed5b2
http://www.sciencedirect.com/science/article/pii/S2212877821001277
http://www.sciencedirect.com/science/article/pii/S2212877821001277